pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

239 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT776Endpoints579BioPharma Dive223onclive165Fierce Biotech53BioSpace52raps22
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology6Hematology
  • <![CDATA[Evolving Strategies for Myelofibrosis-Associated Anemia Highlight Persistent Gaps in Biomarker Guidance]]>
    <![CDATA[Aaron Gerds, MD, MS, and Anthony M. Hunter, MD, break down the challenges of anemia management in myelofibrosis and potential treatment avenues.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Perioperative Durvalumab Plus Neoadjuvant EV Displays EFS, OS Benefits vs SOC in MIBC]]>
    <![CDATA[Perioperative durvalumab plus EV showed positive topline efficacy findings in MIBC.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Rintatolimod Plus Pembrolizumab and Cisplatin Displays 50% ORR in Recurrent Ovarian Cancer]]>
    <![CDATA[The addition of rintatolimod to pembrolizumab and cisplatin demonstrated robust albeit preliminary antitumor activity in patients with recurrent ovarian cancer. ]]>
← prev
page 5 of 10
next →
6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
onclive · 2mo ago
↗ source
  • <![CDATA[Dana-Farber Study Finds Stage IV Breast Cancer Increasing in Incidence and Proportion Over the Last Decade]]>
    <![CDATA[A Dana-Farber study showed cases of stage IV breast cancer are increasing in incidence and as a proportion of all breast cancer diagnoses. ]]>
    onclive · 2mo ago↗ source
  • <![CDATA[REVELUTION-2 Trial Is Evaluating Cardiovascular Risk With Relugolix Plus Abiraterone Acetate in High-Risk Prostate Cancer]]>
    <![CDATA[Sagar A. Patel, MD, discusses the REVELUTION-2 trial evaluating cardiovascular safety with hormone therapy in prostate cancer.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Clinical Implementation and Surveillance Strategies]]>
    <![CDATA[]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Case Introduction and ctDNA as Emerging Risk Factor]]>
    <![CDATA[]]>
    onclive · 2mo ago↗ source
  • <![CDATA[ASCO 2026: All Eyes Are on Daraxonrasib and a Wave of Novel Targeted Therapies in GI Malignancies]]>
    <![CDATA[Ahead of the 2026 ASCO Annual Meeting, experts in GI malignancies share the most anticipated research being presented during the meeting.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[MET Alterations in NSCLC: Amplification, Mutations, and Therapeutic Strategies]]>
    <![CDATA[Decode MET-altered lung cancer: amplification, exon 14 skipping and co-mutations, plus evolving targeted therapies and tumor board insights.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Planned HERIZON-GEA-01 Analyses and the Doublet-vs-Triplet Question]]>
    <![CDATA[New HER2+ gastric cancer data show triplet immunotherapy boosts survival and durable responses, hinting immune activation beyond HER2 targets.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[HERIZON-GEA-01 Efficacy Results and Interpretation of Duration of Response]]>
    <![CDATA[HORIZON-GA01 shows zenidatamab regimens significantly improve survival in HER2-positive gastric cancer, while PD-L1 testing differences raise key questions for treatment choice.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Five-year survival with tebentafusp in previously untreated metastatic uveal melanoma in a phase 3 trial (CT029)]]>
    <![CDATA[Five-year Phase III data show tebentafusp doubles survival in metastatic uveal melanoma, with ctDNA response predicting benefit beyond imaging and progression.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Emerging Biomarkers in NSCLC: TROP2 Scoring and MTAP Loss]]>
    <![CDATA[How Trop2 and MTAP-loss reshape NSCLC therapy, with AI pathology refining ADC response prediction and guiding trial referrals.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Evolving Oral SERD Research Seeks to Redefine Treatment Strategies in Hormone Receptor+ Breast Cancer]]>
    <![CDATA[Breast cancer experts discuss the nuances of ESR1 mutations and oral SERD use in hormone receptor–positive breast cancer.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Immunotherapy Advances in Upfront SCAC Expose Need for Better Second-Line Strategies]]>
    <![CDATA[Aparna R. Parikh, MD, emphasizes the feasibility of immunotherapy trials in SCAC and the need for better treatment options in the second line and beyond. ]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Dr Loghavi on the Significance of Updated WHO Diagnostic Criteria for AML in Clinical Practice]]>
    <![CDATA[Sanam Loghavi, MD, discusses updated WHO diagnostic criteria for acute myeloid leukemia and its significance for diagnoses and treatment selection.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[FDA Approves Decitabine/Cedazuridine Plus Venetoclax in Newly Diagnosed AML]]>
    <![CDATA[The FDA has approved oral decitabine/cedazuridine plus venetoclax for newly diagnosed AML unfit for intensive chemo, based on phase 2 ASCERTAIN-V data.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[FDA Approves Sonrotoclax for Relapsed/Refractory Mantle Cell Lymphoma]]>
    <![CDATA[The FDA granted accelerated approval to sonrotoclax for relapsed/refractory mantle cell lymphoma after at least 2 lines of systemic therapy.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Dr Dinardo on the FDA Approval of Decitabine/Cedazuridine Plus Venetoclax in AML]]>
    <![CDATA[Courtney D. DiNardo, MD, MSCE, discusses the FDA approval of decitabine/cedazuridine plus venetoclax in acute myeloid leukemia. ]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Tirabrutinib and CAR T-Cell Therapy Represent Potential Paradigm Shifts in R/R PCNSL ]]>
    <![CDATA[Ashley Sumrall, MD, FACP, FASCO, discusses emerging data for tirabrutinib and the evolving role of CAR T-cell therapy in primary central nervous system lymphoma.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Future Directions in Metastatic Castration-Resistant Prostate Cancer]]>
    <![CDATA[Dr. Pedro Barata and Dr. Johann De Bono conclude the discussion by reflecting on the evolving future of radiopharmaceutical therapies in metastatic castration-resistant prostate cancer (mC…
    onclive · 2mo ago↗ source
  • <![CDATA[Personalized Treatment Decision-Making in Metastatic Castration-Resistant Prostate Cancer]]>
    <![CDATA[Dr. Johann De Bono and Dr. Pedro Barata discuss the increasing complexity of personalized treatment decision-making in metastatic castration-resistant prostate cancer (mCRPC) as radiopharm…
    onclive · 2mo ago↗ source
  • <![CDATA[Future Radiopharmaceutical Strategies in Metastatic Castration-Resistant Prostate Cancer]]>
    <![CDATA[Dr. Pedro Barata and Dr. Johann De Bono discuss the future direction of radiopharmaceutical therapies and emerging treatment strategies in metastatic castration-resistant prostate cancer (…
    onclive · 2mo ago↗ source
  • <![CDATA[Safety and Toxicity Management in Metastatic Castration-Resistant Prostate Cancer]]>
    <![CDATA[Dr. Johann De Bono and Dr. Pedro Barata discuss practical approaches to monitoring and managing toxicities associated with radiopharmaceutical therapies in metastatic castration-resistant…
    onclive · 2mo ago↗ source
  • <![CDATA[Combination and Sequencing Strategies in Metastatic Castration-Resistant Prostate Cancer]]>
    <![CDATA[Dr. Pedro Barata and Dr. Johann De Bono discuss ongoing questions surrounding combination approaches and optimal sequencing strategies for radiopharmaceutical therapies in metastatic castr…
    onclive · 2mo ago↗ source